October 19, 2012Open Access

Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

SRSaskia M. RombachErasmus MC JAJohannes M. F. G. AertsUniversity of Southern California BPBen J. H. M. PoorthuisLeiden University

Key Points

Key points are not available for this paper at this time.

Abstract

Introduction: Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and lysoGb3 and clinical outcome in Fabry patients on ERT.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Rombach et al. (Fri,) studied this question.

synapsesocial.com/papers/69dba13950e1971baba3c021 https://doi.org/https://doi.org/10.1371/journal.pone.0047805

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper